KALA
KALA BIO, Inc.
Biotechnology
Market Cap$618K
5Y Perf.-100.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
KALA vs HROW vs LNTH vs SGHT
Revenue, margins, valuation, and 5-year total return — side by side.
HROW
Harrow Health, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$1.45B
5Y Perf.+337.8%
LNTH
Lantheus Holdings, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$5.92B
5Y Perf.+247.7%
SGHT
Sight Sciences, Inc.
Medical - Devices
Market Cap$286M
5Y Perf.-85.7%
KALA vs HROW vs LNTH vs SGHT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KALA | HROW | LNTH | SGHT |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Medical - Devices |
| Market Cap | $618K | $1.45B | $5.92B | $286M |
| Revenue (TTM) | $254K | $272M | $1.55B | $80M |
| Net Income (TTM) | $-36M | $-5M | $279M | $-37M |
| Gross Margin | -3.1% | 75.1% | 60.5% | 86.2% |
| Operating Margin | -150.6% | 11.2% | 18.8% | -44.8% |
| Forward P/E | — | 82.9x | 17.5x | — |
| Total Debt | $32M | $252M | $738K | $41M |
| Cash & Equiv. | $51M | $73M | $359M | $92M |
KALA vs HROW vs LNTH vs SGHT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KALA
HROW
LNTH
SGHT
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | 100 | 0.0 | -100.0% |
| Harrow Health, Inc. (HROW) | 100 | 437.8 | +337.8% |
| Lantheus Holdings, … (LNTH) | 100 | 347.7 | +247.7% |
| Sight Sciences, Inc. (SGHT) | 100 | 14.3 | -85.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KALA vs HROW vs LNTH vs SGHT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LNTH leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. KALA BIO, Inc. is the stronger pick specifically for growth and revenue expansion. SGHT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
KALA
KALA BIO, Inc.
The Growth Leader
KALA is the #2 pick in this set and the best alternative if growth is your priority.
- 262.9% revenue growth vs SGHT's -3.1%
Best for: growth
HROW
Harrow Health, Inc.
The Income Pick
HROW is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 2.13
- Rev growth 36.4%, EPS growth 71.4%, 3Y rev CAGR 45.4%
Best for: income & stability and growth exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder
LNTH carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs HROW's 9.1%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
- Beta 0.47, current ratio 2.70x
- Better valuation composite
Best for: long-term compounding and sleep-well-at-night
SGHT
Sight Sciences, Inc.
The Momentum Pick
SGHT is the clearest fit if your priority is momentum.
- +85.0% vs KALA's -97.6%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KALA | 262.9% revenue growth vs SGHT's -3.1% |
| Value | LNTH | Better valuation composite |
| Quality / Margins | LNTH | 18.0% margin vs KALA's -141.1% |
| Stability / Safety | LNTH | Beta 0.47 vs SGHT's 2.49, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | SGHT | +85.0% vs KALA's -97.6% |
| Efficiency (ROA) | LNTH | 12.4% ROA vs KALA's -143.2% |
KALA vs HROW vs LNTH vs SGHT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2025
KALA vs HROW vs LNTH vs SGHT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLNTHLAGGINGSGHT
Who Leads Where
LNTH leads in 3 of 6 categories
HROW leads 1 • KALA leads 0 • SGHT leads 0 • 1 tied
Explore the data ↓SGHTSight Sciences, Inc.
0leads
KALAKALA BIO, Inc.
0leads
HROWHarrow Health, Inc.
1leads
LNTHLantheus Holdings, In…
3leads
6 Total Categories
CATEGORYLEADERvs HROWvs KALAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LNTH3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LNTH9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
HROW3/6
Risk & VolatilityBeta, volatility, and downside exposure
LNTH2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LNTH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LNTH is the larger business by revenue, generating $1.5B annually — 6087.3x KALA's $254,000. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to KALA's -141.1%. On growth, HROW holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KALAKALA BIO, Inc. | HROWHarrow Health, In… | LNTHLantheus Holdings… | SGHTSight Sciences, I… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $254,000 | $272M | $1.5B | $80M |
| EBITDAEarnings before interest/tax | -$38M | $59M | $347M | -$35M |
| Net IncomeAfter-tax profit | -$36M | -$5M | $279M | -$37M |
| Free Cash FlowCash after capex | -$32M | $73M | $372M | -$25M |
| Gross MarginGross profit ÷ Revenue | -3.1% | +75.1% | +60.5% | +86.2% |
| Operating MarginEBIT ÷ Revenue | -150.6% | +11.2% | +18.8% | -44.8% |
| Net MarginNet income ÷ Revenue | -141.1% | -1.9% | +18.0% | -46.8% |
| FCF MarginFCF ÷ Revenue | -126.3% | +26.8% | +24.0% | -31.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +33.3% | +1.2% | +12.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +44.6% | -5.3% | +76.5% | +14.3% |
LNTH leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — KALA and HROW and LNTH and SGHT each lead in 1 of 4 comparable metrics.
Valuation Metrics
| Metric | KALAKALA BIO, Inc. | HROWHarrow Health, In… | LNTHLantheus Holdings… | SGHTSight Sciences, I… |
|---|---|---|---|---|
| Market CapShares × price | $617,676 | $1.5B | $5.9B | $286M |
| Enterprise ValueMkt cap + debt − cash | -$18M | $1.6B | $5.6B | $235M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -278.93x | 26.69x | -7.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 82.86x | 17.52x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 14.61x | — |
| Price / SalesMarket cap ÷ Revenue | — | 5.34x | 3.84x | 3.69x |
| Price / BookPrice ÷ Book value/share | 0.04x | 27.56x | 5.72x | 4.31x |
| Price / FCFMarket cap ÷ FCF | — | — | 16.73x | — |
Evenly matched — KALA and HROW and LNTH and SGHT each lead in 1 of 4 comparable metrics.
Profitability & Efficiency
LNTH leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-4 for KALA. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to HROW's 4.84x. On the Piotroski fundamental quality scale (0–9), LNTH scores 5/9 vs KALA's 2/9, reflecting solid financial health.
| Metric | KALAKALA BIO, Inc. | HROWHarrow Health, In… | LNTHLantheus Holdings… | SGHTSight Sciences, I… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.9% | -10.1% | +24.3% | -59.1% |
| ROA (TTM)Return on assets | -143.2% | -1.4% | +12.4% | -32.2% |
| ROICReturn on invested capital | — | +9.5% | +30.6% | -2.7% |
| ROCEReturn on capital employed | -95.2% | +10.2% | +17.1% | -32.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 5 | 5 |
| Debt / EquityFinancial leverage | 2.62x | 4.84x | 0.00x | 0.64x |
| Net DebtTotal debt minus cash | -$19M | $179M | -$358M | -$51M |
| Cash & Equiv.Liquid assets | $51M | $73M | $359M | $92M |
| Total DebtShort + long-term debt | $32M | $252M | $738,000 | $41M |
| Interest CoverageEBIT ÷ Interest expense | -6.92x | 0.53x | 11.72x | -14.04x |
LNTH leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
HROW leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HROW five years ago would be worth $47,797 today (with dividends reinvested), compared to $3 for KALA. Over the past 12 months, SGHT leads with a +85.0% total return vs KALA's -97.6%. The 3-year compound annual growth rate (CAGR) favors HROW at 12.7% vs KALA's -82.6% — a key indicator of consistent wealth creation.
| Metric | KALAKALA BIO, Inc. | HROWHarrow Health, In… | LNTHLantheus Holdings… | SGHTSight Sciences, I… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -86.6% | -21.8% | +35.3% | -29.3% |
| 1-Year ReturnPast 12 months | -97.6% | +58.8% | +13.1% | +85.0% |
| 3-Year ReturnCumulative with dividends | -99.5% | +43.0% | -4.0% | -49.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | +378.0% | +314.2% | -84.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | +914.3% | +4192.5% | -84.2% |
| CAGR (3Y)Annualised 3-year return | -82.6% | +12.7% | -1.4% | -20.5% |
HROW leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
LNTH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than SGHT's 2.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs KALA's 0.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KALAKALA BIO, Inc. | HROWHarrow Health, In… | LNTHLantheus Holdings… | SGHTSight Sciences, I… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.09x | 2.13x | 0.47x | 2.49x |
| 52-Week HighHighest price in past year | $20.60 | $54.85 | $93.00 | $9.24 |
| 52-Week LowLowest price in past year | $0.08 | $21.12 | $47.25 | $2.81 |
| % of 52W HighCurrent price vs 52-week peak | +0.4% | +71.2% | +97.8% | +57.3% |
| RSI (14)Momentum oscillator 0–100 | 30.1 | 54.6 | 61.2 | 54.2 |
| Avg Volume (50D)Average daily shares traded | 9.2M | 733K | 886K | 357K |
LNTH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: KALA as "Buy", HROW as "Buy", LNTH as "Buy", SGHT as "Buy". Consensus price targets imply 21861.5% upside for KALA (target: $18) vs 11.0% for LNTH (target: $101).
| Metric | KALAKALA BIO, Inc. | HROWHarrow Health, In… | LNTHLantheus Holdings… | SGHTSight Sciences, I… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.25 | $75.67 | $101.00 | $9.67 |
| # AnalystsCovering analysts | 9 | 10 | 17 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +5.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LNTH leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HROW leads in 1 (Total Returns). 1 tied.
Best OverallLantheus Holdings, Inc. (LNTH)Leads 3 of 6 categories
Loading custom metrics...
KALA vs HROW vs LNTH vs SGHT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KALA or HROW or LNTH or SGHT a better buy right now?
For growth investors, Harrow Health, Inc.
(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate KALA BIO, Inc. (KALA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KALA or HROW or LNTH or SGHT?
On forward P/E, Lantheus Holdings, Inc.
is actually cheaper at 17. 5x.
03Which is the better long-term investment — KALA or HROW or LNTH or SGHT?
Over the past 5 years, Harrow Health, Inc.
(HROW) delivered a total return of +378. 0%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KALA or HROW or LNTH or SGHT?
By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.
(LNTH) is the lower-risk stock at 0. 47β versus Sight Sciences, Inc. 's 2. 49β — meaning SGHT is approximately 430% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — KALA or HROW or LNTH or SGHT?
By revenue growth (latest reported year), Harrow Health, Inc.
(HROW) is pulling ahead at 36. 4% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KALA or HROW or LNTH or SGHT?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -150. 6% for KALA. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KALA or HROW or LNTH or SGHT more undervalued right now?
On forward earnings alone, Lantheus Holdings, Inc.
(LNTH) trades at 17. 5x forward P/E versus 82. 9x for Harrow Health, Inc. — 65. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KALA: 21861. 5% to $18. 25.
08Which pays a better dividend — KALA or HROW or LNTH or SGHT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is KALA or HROW or LNTH or SGHT better for a retirement portfolio?
For long-horizon retirement investors, Lantheus Holdings, Inc.
(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +41. 9%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KALA and HROW and LNTH and SGHT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KALA is a small-cap quality compounder stock; HROW is a small-cap high-growth stock; LNTH is a small-cap quality compounder stock; SGHT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.